SKELAXIN Drug Patent Profile

When do Skelaxin patents expire, and when can generic versions of Skelaxin launch?

Skelaxin is a drug marketed by King Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SKELAXIN is metaxalone. There are twenty drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the metaxalone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Skelaxin

A generic version of SKELAXIN was approved as metaxalone by SANDOZ on March 31^st, 2010.

Summary for SKELAXIN

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2,842
Drug Prices:	Drug price information for SKELAXIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SKELAXIN
What excipients (inactive ingredients) are in SKELAXIN?	SKELAXIN excipients list
DailyMed Link:	SKELAXIN at DailyMed

See drug prices for SKELAXIN

See drug sales revenues for SKELAXIN

Paragraph IV (Patent) Challenges for SKELAXIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SKELAXIN	Tablets	metaxalone	800 mg	013217	1	2004-11-04

US Patents and Regulatory Information for SKELAXIN

SKELAXIN is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002		DISCN	Yes	No

Expired US Patents for SKELAXIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-001	Approved Prior to Jan 1, 1982
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-001	Approved Prior to Jan 1, 1982

International Patents for SKELAXIN

See the table below for patents covering SKELAXIN around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2626027
World Intellectual Property Organization (WIPO)	2007094825

Market Dynamics and Financial Trajectory for SKELAXIN (Metaxalone)

Last updated: January 3, 2026

Executive Summary

SKELAXIN (metaxalone), a muscle relaxant approved by the FDA since 1962, has maintained a niche position in the pharmaceutical landscape for the symptomatic relief of acute musculoskeletal conditions. Despite its longstanding presence, SKELAXIN's market trajectory is influenced by evolving healthcare policies, competitive generics, shifting prescribing practices, and emerging alternative therapies. This comprehensive analysis examines the current market dynamics, growth drivers, challenges, and future financial prospects for SKELAXIN.

Introduction

SKELAXIN's active ingredient, metaxalone, is part of the centrally acting muscle relaxants class. It primarily addresses acute muscle spasms associated with musculoskeletal injuries. Its market presence is characterized by moderate prescription volumes, generic competition, and limited direct marketing.

Key Data Points

Parameter	Details
Approved FDA Date	1962
Dosage Forms	Tablets (800 mg)
Daily Dosing	Typically 800 mg three to four times daily
Estimated Global Market Size	$150 million (U.S. market, 2022 estimate)
Prescriptions (U.S., 2022)	Approx. 1.2 million prescriptions
Market Share (generics)	~85% (dominated by generic manufacturers)

---

What are the Market Dynamics Influencing SKELAXIN?

How Is the Aging Population Affecting Demand?

The aging demographic increases incidence of musculoskeletal issues, potentially elevating SKELAXIN's prescription rates.

• Data Point: The U.S. Census Bureau (2020) projects adults aged 65+ will comprise over 20% of the population by 2030.
• Impact: Higher prevalence of conditions requiring muscle relaxation (e.g., back spasms) sustains demand, but this is tempered by alternative therapies and regulatory shifts.

What Role Do Prescribing Trends and Clinical Guidelines Play?

Recent trends favor non-opioid pain management and multimodal therapies.

• Policy Shift: The CDC’s 2016 guidelines for pain management discourage opioid use, promoting alternative therapies.
• Implication: Physicians may prefer non-sedating or non-muscle relaxant options for acute pain, limiting SKELAXIN's growth.

How Does Competition from Generics and Alternatives Influence Market Share?

• Generics: Over 85% of SKELAXIN prescriptions are fulfilled by generics, exerting price competition.
• Alternatives: Agents like carisoprodol (Soma), cyclobenzaprine, and baclofen see increasing off-label use.

Competitor	Market Position	Key Differentiator
Carisoprodol	Slightly superior prescribing trends	Controlled substance status affects use
Cyclobenzaprine	Expanding use	Long-term safety profile
Baclofen	Specialized use	For spasticity, less for acute muscle spasms

How Do Regulatory and Policy Changes Impact SKELAXIN?

• Controlled Substance Scheduling: SKELAXIN is not scheduled; however, increased scrutiny of muscle relaxants influences prescribing.
• FDA Initiatives: Emphasis on opioid alternatives has partially benefited SKELAXIN but also encouraged the adoption of other modalities.

---

What Is the Financial Trajectory for SKELAXIN?

Historical Revenue Trends

Year	Estimated Revenue	Prescription Volume	Comments
2018	~$50 million	~1.5 million	Slight decline due to rising generic competition
2020	~$45 million	~1.3 million	FDA focus on opioid reduction impacts prescribing
2022	~$42 million	~1.2 million	Continued commoditization of the product

Revenue Drivers and Challenges

Drivers	Impact
Stable demand in acute musculoskeletal pain	Sustains baseline revenue
Generic price erosion	Reduces revenue per prescription
Market saturation	Limits growth prospects
Emerging therapies and protocols	Shift toward multimodal or non-pharmacological treatments

Forecasting Future Market Trajectory

Forecast Assumptions:

• Moderate annual decline of 2-3% in revenue due to generics and competition.
• Potential stabilization owing to brand loyalty among prescribers and insurance formulary preferences.
• Growth opportunities are minimal unless new indications or formulations are developed.

Forecast Year	Estimated Revenue	Key Factors
2025	~$38 million	Continued generics competition, stable demand
2030	~$35 million	Market saturation, alternate therapies prevalent

---

How Do Innovations and Policy Changes Affect SKELAXIN?

What Innovations Could Alter Market Dynamics?

• Formulation enhancements: Development of extended-release or combined formulations.
• New indications: Clinical trials for chronic muscle spasm or spasticity.
• Delivery methods: Injectable or transdermal delivery systems.

Are There Policy Trends Favoring or Hindering SKELAXIN's Market?

• Drug pricing policies: Focus on reducing healthcare costs may limit pricing power.
• Reimbursement trends: Favoring cost-effective generics; SKELAXIN's low-cost profile maintains competitiveness.
• Drug scheduling: Non-controlled status limits restrictions but also reduces regulatory spotlight.

---

How Does SKELAXIN Compare with Similar Drugs?

Aspect	SKELAXIN (Metaxalone)	Cyclobenzaprine	Carisoprodol
FDA Classification	Non-controlled	Controlled (Schedule IV)	Controlled (Schedule IV)
Typical Dose	800 mg TID	10 mg TID	350 mg TID
Duration of Use	Short-term (typically 2-3 weeks)	Short-term	Short to medium-term
Side Effect Profile	Sedation, dizziness	Drowsiness, dry mouth	Drowsiness, dependence risk

Note: The choice among these agents depends on clinician preference, patient profiles, and regulatory considerations.

---

What Are the Future Opportunities and Risks?

Opportunities

• Expansion into new markets: Emerging economies with increasing musculoskeletal disorders.
• Formulation innovation: Novel delivery systems.
• Clinical research: Demonstrating efficacy in broader indications.

Risks

• Market commoditization: Price competition from generics.
• Regulatory constraints: Potential scheduling of similar agents impacting prescribing.
• Competition from non-pharmacological therapies: Physical therapy, acupuncture.

---

Key Takeaways

• SKELAXIN’s market is primarily driven by demand for short-term muscle relaxation in acute conditions, but faces significant headwinds from generic competition and shifting prescribing trends favoring multimodal pain management.
• Revenue has experienced a slow decline, with forecasts projecting continued modest erosion unless innovative formulations or new indications emerge.
• The drug's non-controlled status affords regulatory flexibility but also limits emergency regulatory interventions that could bolster its market share.
• Future growth hinges on market expansion into emerging economies and potential strategic formulation innovations.
• Deepening integration of non-pharmacological treatments and comprehensive pain management strategies could further limit SKELAXIN’s market growth.

---

FAQs

1. What factors influence the prescribing of SKELAXIN compared to other muscle relaxants?

Prescribing is influenced by efficacy, side effect profiles, regulatory status, clinician familiarity, and formulary preferences. SKELAXIN's non-controlled status and lower side effect profile make it a preferred choice for some practitioners.

2. Are there any promising new formulations or indications for SKELAXIN?

Currently, no significant new formulations or indications are approved. Clinical research exploring chronic spasticity or combination therapies could potentially expand its use.

3. How does healthcare policy impact SKELAXIN’s market?

Policies favoring non-opioid treatments and cost-effective generics support SKELAXIN’s continued market existence but also intensify price competition.

4. What is SKELAXIN’s competitive advantage in a saturated generic market?

Limited; its main advantage is brand recognition and clinician familiarity, but this is overshadowed by aggressive generic price reductions.

5. Can SKELAXIN reverse the current declining trend?

Potentially, through innovation or clinical breakthroughs, but the current market environment favors multiple competing agents and non-pharmacological alternatives.

---

References

1. Food and Drug Administration (FDA). Approved Drug Products: SKELAXIN. 1962.
2. U.S. Census Bureau. Population Estimates and Projections. 2020.
3. IQVIA. Pharmaceutical Market Data. 2022.
4. Centers for Disease Control and Prevention (CDC). Guidelines for Prescribing Pain Medications. 2016.
5. MarketWatch. Pharmaceutical Market Analysis. 2022.

---

This detailed review provides a strategic lens for stakeholders evaluating the economic and clinical positioning of SKELAXIN in an evolving healthcare landscape.